ATE463258T1 - Verzögerte freigabe von mikrokristallin peptidsuspensionen - Google Patents

Verzögerte freigabe von mikrokristallin peptidsuspensionen

Info

Publication number
ATE463258T1
ATE463258T1 AT02772214T AT02772214T ATE463258T1 AT E463258 T1 ATE463258 T1 AT E463258T1 AT 02772214 T AT02772214 T AT 02772214T AT 02772214 T AT02772214 T AT 02772214T AT E463258 T1 ATE463258 T1 AT E463258T1
Authority
AT
Austria
Prior art keywords
delayed release
peptide suspensions
microcrystalline peptide
microcrystalline
suspensions
Prior art date
Application number
AT02772214T
Other languages
English (en)
Inventor
Romano Deghenghi
Francois Boutignon
Original Assignee
Ardana Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardana Bioscience Ltd filed Critical Ardana Bioscience Ltd
Application granted granted Critical
Publication of ATE463258T1 publication Critical patent/ATE463258T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT02772214T 2001-09-06 2002-08-27 Verzögerte freigabe von mikrokristallin peptidsuspensionen ATE463258T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31761601P 2001-09-06 2001-09-06
PCT/EP2002/009537 WO2003022243A2 (en) 2001-09-06 2002-08-27 Sustained release of microcrystalline peptide suspensions

Publications (1)

Publication Number Publication Date
ATE463258T1 true ATE463258T1 (de) 2010-04-15

Family

ID=23234486

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02772214T ATE463258T1 (de) 2001-09-06 2002-08-27 Verzögerte freigabe von mikrokristallin peptidsuspensionen

Country Status (26)

Country Link
US (5) US7098305B2 (de)
EP (2) EP2198888B1 (de)
JP (3) JP2005504787A (de)
KR (2) KR100818904B1 (de)
CN (1) CN100386116C (de)
AR (1) AR042592A1 (de)
AT (1) ATE463258T1 (de)
AU (1) AU2002337025B2 (de)
BR (1) BR0212333A (de)
CA (1) CA2459309C (de)
CY (1) CY1118642T1 (de)
DE (1) DE60235896D1 (de)
DK (1) DK2198888T3 (de)
ES (2) ES2362505T3 (de)
HU (1) HUP0402099A2 (de)
IL (1) IL160443A0 (de)
MX (1) MXPA04002185A (de)
NO (1) NO20040938L (de)
NZ (1) NZ531734A (de)
PL (1) PL368056A1 (de)
PT (1) PT2198888T (de)
RU (1) RU2311195C2 (de)
TW (1) TWI249409B (de)
UA (1) UA79435C2 (de)
WO (1) WO2003022243A2 (de)
ZA (1) ZA200401390B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
ES2369542T3 (es) * 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
CA2637569C (en) * 2006-01-18 2013-01-08 Yuhua Li Pharmaceutical compositions with enhanced stability
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
WO2008071984A1 (en) * 2006-12-13 2008-06-19 Ardana Bioscience Limited Administration of the gonadotropin-releasing hormone antagonist teverelix
PT2474557E (pt) 2007-07-16 2014-12-03 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
KR101795643B1 (ko) * 2009-05-01 2017-11-09 훼링 비.브이. 전립선암 치료용 조성물
KR101915820B1 (ko) 2010-01-13 2018-11-06 입센 파마 에스.에이.에스 소마토스타틴 유사체의 지속 방출을 위한 제약 조성물의 제조 방법
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012006566A2 (en) * 2010-07-09 2012-01-12 Amylin Pharmaceuticals, Inc. Microcrystalline y receptor agonists
EP2661273A4 (de) 2011-01-07 2014-06-04 Merrion Res Iii Ltd Pharmazeutische zusammensetzungen aus eisen zur oralen verabreichung
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
EP2823808A1 (de) 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmazeutische Zusammensetzung für eine verzögerte Freisetzung von Lanreotid
EP2832361A1 (de) * 2013-07-29 2015-02-04 Ipsen Pharma S.A.S. Wässrige Zusammensetzungen mit verzögerter Freisetzung von LHRH-Analoga
CN104844694A (zh) * 2014-02-17 2015-08-19 深圳翰宇药业股份有限公司 一种醋酸加尼瑞克的制备方法
JP6417421B2 (ja) 2014-02-28 2018-11-07 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 荷電連結体及び共役体のためのその使用
CA2979671C (en) 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
EP3307749A4 (de) 2015-06-15 2019-06-19 Hangzhou Dac Biotech Co., Ltd Hydrophile linker für konjugation
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20220147719A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
JP6990717B2 (ja) * 2017-01-30 2022-02-03 アンテヴ リミテッド 少なくとも１種のｇｎｒｈアンタゴニストを含む組成物
JP2020525528A (ja) 2017-06-30 2020-08-27 アンテブ リミテッド 急性尿閉を治療するための組成物を含むシリンジ
EP3560555A1 (de) * 2018-04-26 2019-10-30 LifeArc Zusammensetzung zur behandlung einer oder mehrerer östrogenvermittelter krankheiten
MA52794A (fr) * 2018-05-28 2021-04-14 Jiangyin Usun Pharmaceutical Co Ltd Nouvelle utilisation pharmaceutique
EP3590525A1 (de) * 2018-07-05 2020-01-08 Antev Limited Teverelix-tfa-zusammensetzung
EP3590524B1 (de) * 2018-07-05 2020-11-04 Antev Limited Eine methode zur rekonstitution einer teverelix-tfa-zusammensetzung
EP3590526A1 (de) 2018-07-05 2020-01-08 Antev Limited Lyophilisierungsverfahren und dadurch hergestelltes teverelix-tfa-lyophilisat
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2668866A (en) * 1951-08-14 1954-02-09 Shell Dev Isomerization of paraffin wax
GB1245187A (en) 1969-02-14 1971-09-08 Continental Can Co Hot melt adhesive composition
JPS5242506A (en) 1975-10-02 1977-04-02 Toa Nenryo Kogyo Kk Hydrotreating process of petroleum wax
JPS5335705A (en) * 1976-09-14 1978-04-03 Toa Nenryo Kogyo Kk Hydrogenation and purification of petroleum wax
US4186078A (en) * 1977-09-12 1980-01-29 Toa Nenryo Kogyo Kabushiki Kaisha Catalyst and process for hydrofining petroleum wax
US4239546A (en) * 1978-07-21 1980-12-16 Petrolite Corporation Hydrocarbon polymers to improve the hardness of waxes
US4256737A (en) 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US4266737A (en) * 1979-11-05 1981-05-12 Arrow Converting Equipment, Inc. Air differential mandrel and method of differentially winding and rewinding tapes
US4415649A (en) * 1981-02-25 1983-11-15 E. I. Du Pont De Nemours & Co. Flexographic printing plates containing blended adhesives
US4839422A (en) * 1987-12-23 1989-06-13 Exxon Chemical Patents Inc. Ternary adhesive compositions
DE68928278T2 (de) 1988-02-10 1998-03-12 Tap Pharmaceuticals Inc Lhrh-analog
US5110904A (en) * 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
JP2672677B2 (ja) 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
ATE144538T1 (de) * 1991-04-25 1996-11-15 Romano Deghenghi Lhrh-antagonisten
ES2127835T3 (es) * 1992-10-26 1999-05-01 Sanol Arznei Schwarz Gmbh Procedimiento para la preparacion de microcapsulas.
CA2136078A1 (en) 1992-12-04 1994-06-23 Jonathan Greer 6-position modified decapeptide lhrh antagonists
CA2136079A1 (en) 1992-12-18 1994-07-07 Fortuna Haviv Lhrh antagonists having modified aminoacyl residues at positions 5 and 6
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
CA2178592C (en) * 1993-12-09 2009-07-28 Zentaris Gmbh Long-acting injection suspensions and a process for their preparation
JP3101695B2 (ja) 1996-07-24 2000-10-23 日本航空電子工業株式会社 軟ｘ線光学素子用多層膜
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
DE19813849A1 (de) * 1998-03-27 1999-09-30 Degussa Verfahren zur einstufigen Umsalzung und Aufreinigung von Oligopeptiden
CO5160256A1 (es) 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
DE10040700A1 (de) * 2000-08-17 2002-02-28 Asta Medica Ag Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
JP4505750B2 (ja) 2006-01-27 2010-07-21 東海ゴム工業株式会社 制振装置

Also Published As

Publication number Publication date
UA79435C2 (en) 2007-06-25
KR20040037077A (ko) 2004-05-04
CA2459309C (en) 2012-04-03
EP1423150B1 (de) 2010-04-07
PT2198888T (pt) 2017-02-10
DK2198888T3 (en) 2017-02-13
ES2362505T3 (es) 2011-07-06
JP2005504787A (ja) 2005-02-17
US20100239683A1 (en) 2010-09-23
HK1062148A1 (en) 2004-10-21
RU2004110615A (ru) 2005-05-10
AU2002337025B2 (en) 2006-12-07
NO20040938D0 (no) 2004-03-04
JP2013177449A (ja) 2013-09-09
EP2198888A3 (de) 2011-08-31
CY1118642T1 (el) 2017-07-12
TWI249409B (en) 2006-02-21
ES2618777T3 (es) 2017-06-22
US20030044463A1 (en) 2003-03-06
CN100386116C (zh) 2008-05-07
ZA200401390B (en) 2004-08-27
US20110312889A1 (en) 2011-12-22
EP1423150A2 (de) 2004-06-02
WO2003022243A3 (en) 2003-10-30
JP2010095533A (ja) 2010-04-30
WO2003022243A2 (en) 2003-03-20
US20060229238A1 (en) 2006-10-12
US8415300B2 (en) 2013-04-09
CN1551785A (zh) 2004-12-01
HUP0402099A2 (hu) 2005-02-28
EP2198888A2 (de) 2010-06-23
MXPA04002185A (es) 2004-07-23
KR20070107161A (ko) 2007-11-06
BR0212333A (pt) 2004-09-21
US7098305B2 (en) 2006-08-29
KR100818904B1 (ko) 2008-04-04
CA2459309A1 (en) 2003-03-20
NZ531734A (en) 2006-02-24
JP5757686B2 (ja) 2015-07-29
EP2198888B1 (de) 2016-11-02
RU2311195C2 (ru) 2007-11-27
IL160443A0 (en) 2004-07-25
PL368056A1 (en) 2005-03-21
AR042592A1 (es) 2005-06-29
DE60235896D1 (de) 2010-05-20
US20060228385A1 (en) 2006-10-12
NO20040938L (no) 2004-06-04

Similar Documents

Publication Publication Date Title
DE60235896D1 (de) Verzögerte freigabe von mikrokristallin peptidsuspensionen
ATE519741T1 (de) Racemattrennung von (1-benzyl-4-methylpiperidin-3-yl)-methylamin
EP1578771A4 (de) Remodellierung und glycokonjugation von peptiden
DE60224791D1 (de) Gewindeverbindung
DE60236581D1 (de) Ng von mosaikeffekten
DK1360169T3 (da) Succinatsalt af O-desmethyl-venlafaxin
EP1294513A4 (de) Lokalisationsspezifische kovalente biokonjugation von proteinen
DK1236859T3 (da) Tidsforsinket forbindelseslås
DE60210864D1 (de) Modifiziertes fluoreszentes Protein
DE02784674T1 (de) Quantifizierung von polypeptiden
DE50201549D1 (de) Rückflussverhinderer
NO20034452L (no) Sykdoms-assosiert protein
DE50107986D1 (de) Luftfederbalg
BR0207810A (pt) inibidores de deformilase de peptìdeo
IS2523B (is) Turn vindorkuvers
DE50205704D1 (de) Verbundanker
EP1367996A4 (de) Suspension von ceftiofur-hydrochlorid mit verzögerter freisetzung
DE50206669D1 (de) Fadengreifer
DK1392722T3 (da) Fremgangsmåde vedrörende echinocandiner
EP1359932A4 (de) Tip39 polypeptide
DE60031450D1 (de) Polymorph v von torasemid
NO20032963L (no) Peptidforbindelser
DE50102501D1 (de) Elektrostatischer korrektor
DE60007360D1 (de) Amorphe modifikation von torasemid
DE60208824D1 (de) Verbesserungen von elektromechanischen aktuatoren